Page
%P
![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessCorrection to: The genomic signature of resistance to platinum-containing neoadjuvant therapy based on single-cell data
-
Article
Open AccessThe genomic signature of resistance to platinum-containing neoadjuvant therapy based on single-cell data
Neoadjuvant chemotherapy (NACT) becomes the first-line option for advanced tumors, while patients who are not sensitive to it may not benefit. Therefore, it is important to screen patients suitable for NACT.